التفاصيل البيبلوغرافية
| العنوان: |
P.014 Intravenous immunoglobulin use for central nervous system disorders in British Columbia: implementation of a provincial screening program |
| المؤلفون: |
Beadon, K, Uy, C, Cross, H, Hrazdil, C, Percy, J, Jiwa, N, Schrader, D, Beauchamp, A, Rosinski, K, Carruthers, R, Traboulsee, A, Shih, A, Morrison, D, Chapman, KM |
| المصدر: |
The Canadian Journal of Neurological Sciences; June 2024, Vol. 51 Issue: Supplement 1 pS18-S18, 1p |
| مستخلص: |
Background: Intravenous Immunoglobulin (IVIg) use for Central Nervous System (CNS) conditions has increased over the last decade. In many CNS disorders, robust evidence for IVIg efficacy is still lacking. Building on the success of the British Columbia (BC) Neuromuscular IVIg utilization initiative, Guidelines for IVIg use in CNS conditions were developed. A provincial screening program was launched in 2023. Methods: For CNS IVIg, requests, diagnosis, dosing, consultation letters and treatment questionnaires were reviewed. Patient management was compared to provincial guidelines. A letter was sent to the ordering physician with the results of the review and treatment recommendations when management differed significantly from guidelines. Review of the first year’s cases was conducted. Results: Over the first 11 months of the program, 79 IVIg renewal requests were reviewed. The most common diagnoses were antibody mediated autoimmune encephalitis, severe drug resistant non-surgical epilepsy and Susac’s syndrome. Recommendations included dose reduction, discontinuation of IVIg, or initiation of alternative therapies for many of the requests. Conclusions: IVIg may be effective in the management of some CNS inflammatory conditions. A physician-led utilization program in BC with targeted education to ordering physicians promotes best practice. Review of year one data will inform a quality improvement cycle to optimize the guidelines. |
| قاعدة البيانات: |
Supplemental Index |
